Sangamo Therapeutics Inc SGMO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SGMO is a good fit for your portfolio.
News
-
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
-
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
-
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
-
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
-
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
-
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
-
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Trading Information
- Previous Close Price
- $0.58
- Day Range
- $0.57–0.61
- 52-Week Range
- $0.29–1.67
- Bid/Ask
- $0.61 / $0.61
- Market Cap
- $126.27 Mil
- Volume/Avg
- 837,014 / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 405
- Website
- https://www.sangamo.com
Comparables
Valuation
|
Metric
|
SGMO
|
AKBA
|
BIVI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.06 | — | 1.39 |
Price/Sales | 5.43 | 1.09 | — |
Price/Cash Flow | — | 30.18 | — |
Price/Earnings
SGMO
AKBA
BIVI
Financial Strength
|
Metric
|
SGMO
|
AKBA
|
BIVI
|
|---|---|---|---|
Quick Ratio | 1.37 | 1.03 | 2.43 |
Current Ratio | 1.71 | 1.70 | 2.45 |
Interest Coverage | — | −5.18 | −9.50 |
Quick Ratio
SGMO
AKBA
BIVI
Profitability
|
Metric
|
SGMO
|
AKBA
|
BIVI
|
|---|---|---|---|
Return on Assets (Normalized) | −22.55% | −13.51% | −115.58% |
Return on Equity (Normalized) | −35.70% | — | −256.00% |
Return on Invested Capital (Normalized) | −34.64% | −86.71% | −130.07% |
Return on Assets
SGMO
AKBA
BIVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Gngbvxwgp | Fggb | $639.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pmqjztz | Snnmhx | $124.7 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cxydzmzx | Jddddkz | $110.5 Bil | |||
| Moderna Inc
MRNA
| Ntkxqpyr | Kbpk | $57.9 Bil | |||
| BioNTech SE ADR
BNTX
| Lgmrsrzv | Jptxb | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Mdzknywb | Tprv | $22.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gmmsplbj | Bglhcw | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cdnzdlzgr | Hwjclt | $15.3 Bil | |||
| Incyte Corp
INCY
| Rdnnxjyc | Gpgmnf | $13.3 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Vtnxxgwn | Smxqxrd | $12.4 Bil |